Statement from JDRF on the U.S. Food and Drug Administration (FDA) authorization of the Tidepool Loop:

“The U.S. Food and Drug Administration (FDA) authorization of the Tidepool Loop is a huge win for the type 1 diabetes (T1D) community and is a vital step towards a world where people with T1D can choose the pump, CGM, and algorithm that are best for them—and have all three work together seamlessly.

As part of our mission to improve the lives of those affected by T1D, JDRF has been a leader in artificial pancreas research for more than 15 years and partnered with the FDA to establish regulatory pathways to ensure artificial pancreas technology gets into the hands of people with T1D as quickly as possible. Today, several FDA-approved systems are on the market as a result of that work.

As part of the Artificial Pancreas Program, JDRF—in addition to The Leona M. and Harry B. Helmsley Charitable Trust, Tullman Foundation, and partnerships with device makers and donations from the T1D community—supported the development of the algorithm and preclinical and clinical research through grants to Tidepool.

This approval is also a testament to the spirit of the T1D community. JDRF will continue to support the development of new technologies and treatments to improve blood sugar management to ensure people with T1D can live healthier and more manageable lives until we find cures. JDRF is also fighting to ensure people with this disease have more choices and better access to the diabetes management tools that work best for them.”